A regulatory perspective in Drug Safety examines why switching from an innovator brand to a generic, or between generics, is sometimes followed by reports of adverse effects or loss of effect, even though generics must meet bioequivalence standards. The authors argue that establishing a causal link is hard, and look at how the regulatory framework for approving generics may contribute to the unease. They also raise a possible role for pharmacogenetics.
The paper is a narrative review without new data. It makes no claim that approved generics are unsafe, and it does not provide numbers on the size of any problem.
In practice, the issue matters most for drugs with narrow therapeutic windows, where small differences in exposure can matter, and for patients whose control changes after a switch. Reporting and monitoring, not assumption, are how real problems are found.
- Record the brand or manufacturer when a patient's control changes after a switch
- For narrow therapeutic index drugs, consider checking drug levels or the relevant clinical measure after a switch
- Report suspected therapeutic failure or adverse effects after a switch through pharmacovigilance
- Approved generics meet bioequivalence standards; do not assume a switch is the cause without checking other causes
Why it matters
Cost-driven switching is routine in India, and a clear approach to monitoring prevents both missed problems and wrongly blaming a generic.
Don't overread it
It is a narrative perspective, not evidence that generics cause harm.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free